Current progress in systemic therapy for biliary tract cancers
Authors:
- 18 March 2021
- journal article
- review article
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 29 (10) , 1094-1107
Abstract
Background Biliary tract cancers (BTCs) are heterogeneous cancers that include cancers of the bile duct and gallbladder. Although they are relatively uncommon, most patients with BTC are diagnosed at advanced‐stage disease with high mortality rates. Recently, systemic therapy options for patients with BTC have evolved. This paper reviews recent advancements in systemic therapy and the results of key clinical trials in BTC. Methods A literature search in PubMed and Google Scholar was performed using keywords related to BTC and systemic therapy. Studies that were presented in major international cancer research conferences were also included. Results The evidence shows that adjuvant capecitabine has been associated with a lower relapse rate in early‐stage BTC. In unselected patients with advanced BTC, combination chemotherapy is a standard treatment option. However, with better understanding of the molecular profile of BTC, there has been a shift toward targeted agents in BTC that have shown promising response. The evolving data also support evolving role of immunotherapy in patients with deficient DNA mismatch repair or PD‐L1‐positive BTC. Discussion Systemic treatment options for BTC has improved. The future identification of new targets, novel compounds, and predictive markers is a key step toward the use of personalized medicine in BTC.Keywords
This publication has 76 references indexed in Scilit:
- Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapiesOncogene, 2013
- Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinomaBritish Journal of Cancer, 2011
- Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in JapanBritish Journal of Cancer, 2010
- Sorafenib in patients with advanced biliary tract carcinoma: a phase II trialBritish Journal of Cancer, 2009
- Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trialsBritish Journal of Cancer, 2009
- Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinomaBritish Journal of Cancer, 2009
- Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II studyBritish Journal of Cancer, 2008
- Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinomaBritish Journal of Cancer, 2007
- Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trialsBritish Journal of Cancer, 2007
- Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancerBritish Journal of Cancer, 2006